Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer

Description

Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (\>50%) risk of future life-threatening recurrences and death.

Conditions

Breast Cancer, Residual

Talk to us

Study Overview

On this page

Study Details

Study overview

Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (\>50%) risk of future life-threatening recurrences and death.

Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer Who Have Residual Disease After Neoadjuvant Systemic Therapy

Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥18 years.
  • * Diagnosis of invasive breast cancer treated with neoadjuvant systemic therapy.
  • * Surgically resectable disease following neoadjuvant systemic treatment.
  • * At least one of the following must be true:
  • 1. Received at least 2 weeks of neoadjuvant endocrine therapy
  • 2. Received at least 2 months of neoadjuvant chemotherapy with suggestion of residual disease on imaging
  • 3. Began neoadjuvant chemotherapy or endocrine therapy but discontinued due to evidence of progressive disease by MRI, ultrasound, or physical examination
  • * Provide written informed consent.
  • * Willing to return to enrolling institution for breast cancer surgery.
  • * Willingness to provide mandatory blood specimens for future research on breast cancer at Mayo Clinic.
  • * Willingness to provide mandatory tissue specimens for future research on breast cancer at Mayo Clinic.
  • * Willingness to provide mandatory tissue specimens for the generation of PDX and organoids to be used future research on breast cancer at Mayo Clinic.
  • * Ineligible for surgery.
  • * History of prior malignancy \<3 years prior to registration. Exceptions for non-melanoma skin cancer, papillary thyroid cancer, non-invasive cancer (e.g., carcinoma in situ of the cervix).

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Judy C. Boughey, M.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic

Matthew P. Goetz, M.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2042-01-15